Market Momentum: Biosimilars in 2025

As market dynamics shift and plan priorities evolve, biosimilars have emerged as a powerful lever in lowering healthcare costs while expanding access to essential therapies.  

The biosimilar pipeline has expanded greatly, particularly around highly utilized, costly reference products such as Humira^® and Stelara^®. The growing number of FDA-approved biosimilars has heightened competition, driving price reductions of up to 80-85% compared to their name brand counterparts and improving accessibility to critical therapies.  

As patent protections for several biologics approach their expiration, a growing number of more affordable biosimilar options are poised for debut.

PBDRX Biosimilar Philosophy: Therapeutically Equivalent Drugs at the Lowest Net Cost

At PBDRx, our proactive approach critically evaluates the balance between clinical outcomes and cost effectiveness on each and every drug, including biosimilars, to ensure safety, efficacy, and value. Our expert team works alongside our clients to translate market developments into optimized formulary decisions that drive measurable value.

Biosimilars continue to reshape how we approach access and affordability for plans and patients. As your trusted advisor, PBDRx remains committed to gathering strategic insights and navigating the evolving biosimilar landscape with precision and expertise to deliver our partners with the highest quality therapies at the lowest net cost.

Unlock the full potential of PBDRx’s Biosimilar Philosophy – fill out the form to download the full whitepaper!